Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
Sanofi (NASDAQ:SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds.
Sanofi Aventis (SNY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 13,566,329 | $752,388,622 | +9% | 0.33% |
| 2. | Millennium Management Israel Englander | 1,082,793 | $60,051,700 | +267% | 0.03% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 846,415 | $46,942,176 | +203% | 0.04% |
| 4. | VGI Partners Robert M. P. Luciano | 765,366 | $42,447,198 | +6% | 4.35% |
| 5. | Armistice Capital Steven Boyd | 524,000 | $29,061,040 | -59% | 0.44% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 73,193,057 | $4,059,286,941 | 2.31% | |
| 2. | 11,859,545 | $657,730,379 | 0.12% | |
| 3. | 10,407,790 | $577,216,022 | 0.05% | |
| 4. | 8,323,947 | $461,646,101 | 0.07% | |
| 5. | 8,011,004 | $444,290,476 | 0.03% |
News See All
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now.
11 Best Drug Stocks to Buy According to Hedge Funds
Health and Human Services Secretary Robert F. Kennedy Jr.
Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success
Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with Regeneron Pharmaceuticals, marking a significant advance in COPD treatment...
Stifel Maintains Buy Rating on Nurix (NRIX) Stock
On June 3, Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a price target of $35.
Morgan Stanley Resumes Sanofi (SNY) Coverage, Assigns Equal Weight Rating
On June 2, Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a $56 price target.
Regeneron (REGN) Downgraded at RBC Capital, Price Target Cut Sharply
On May 30, RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc.
Sanofi (SNY)'s MenQuadfi Becomes First MenACWY Vaccine Approved for Ages 6 Weeks and Up
The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old.
Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal
Sanofi (NASDAQ:SNY) has announced a deal to acquire Vigil Neuroscience, a clinical-stage biotech company, for around $470 million, aiming to strengthen its research pipeline with a potential new Alzheimer...
Sanofi (SNY): A Bull Case Theory
We came across a bullish thesis on Sanofi (SNY) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on SNY.